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sleep-related hypermotor epilepsy
ABSTRACT
The syndrome known as nocturnal frontal lobe epilepsy is recognized worldwide and has been studied
in a wide range of clinical and scientific settings (epilepsy, sleepmedicine, neurosurgery, pediatric neu-
rology, epidemiology, genetics). Though uncommon, it is of considerable interest to practicing neurol-
ogists because of complexity in differential diagnosis frommore common, benign sleep disorders such
as parasomnias, or other disorders like psychogenic nonepileptic seizures.Moreover, misdiagnosis can
have substantial adverse consequences on patients’ lives. At present, there is no consensus definition
of this disorder and disagreement persists about its core electroclinical features and the spectrum of
etiologies involved. To improve the definition of the disorder and establish diagnostic criteria with
levels of certainty, a consensus conference using formal recommended methodology was held in
Bologna in September 2014. It was recommended that the name be changed to sleep-related hyper-
motor epilepsy (SHE), reflecting evidence that the attacks are associatedwith sleep rather than time of
day, the seizures may arise from extrafrontal sites, and the motor aspects of the seizures are char-
acteristic. The etiology may be genetic or due to structural pathology, but in most cases remains
unknown. Diagnostic criteria were developed with 3 levels of certainty: witnessed (possible) SHE,
video-documented (clinical) SHE, and video-EEG-documented (confirmed) SHE. Themain research gaps
involve epidemiology, pathophysiology, treatment, and prognosis. Neurology® 2016;86:1834–1842
GLOSSARY
ADSHE5 autosomal dominant sleep-related hypermotor epilepsy; FFEVF5 familial focal epilepsy with variable foci;MFSI5
migrating focal seizures of infancy; mTOR 5 mammalian target of rapamycin; nAChR 5 neuronal acetylcholine receptor;
NFLE 5 nocturnal frontal lobe epilepsy; NREM 5 non-REM; PSG 5 polysomnography; SHE 5 sleep-related hypermotor
epilepsy; SUDEP 5 sudden unexpected death in epilepsy.
Nocturnal frontal lobe epilepsy (NFLE) was first described in 1981, in 5 patients with a peculiar
motor disorder confined to sleep, characterized by violent limb movements or tonic-dystonic
postures.1 Investigators debated for several years about whether this was an epileptic phenom-
enon or a new movement disorder.
Subsequently, similarity of the attacks to those in patients with frontal lobe epilepsy under-
going neurosurgical evaluation2,3 and demonstration of epileptiform discharges in some patients4
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strongly suggested that these attacks were epi-
leptic seizures. Insights into the biology
occurred with the discovery of an autosomal
dominant form5 and identification of the first
gene, CHRNA4, encoding a neuronal nico-
tinic receptor subunit.6
This disorder is of interest to a broad spec-
trum of specialists, from child neurologists to
neurosurgeons. Distinction from nonepileptic
paroxysmal behaviour occurring physiologically
or pathologically during sleep is often difficult
or impossible on clinical grounds alone, and
misdiagnosis is common.5,7 Poor recognition
and misdiagnosis have multiple negative con-
sequences, including unnecessary, costly inves-
tigations, ineffective and potentially harmful
therapeutic regimens, and adverse psychosocial
effects of erroneous epilepsy diagnosis.
Today, disagreement persists on key clinical
features and criteria needed for diagnosis. Thus,
a consensus development conference including
experts in adult and pediatric epileptology, sleep
medicine, and epidemiology was convened in
Bologna on August 30–September 1, 2014.
The aims of the conference were to (1) define
the clinical features of the disorder, (2) define
the electroclinical characteristics of the seizures,
(3) establish diagnostic criteria with levels of
certainty, (4) assess evidence for etiology, and
(5) define research needs.
METHODS The method was inspired by the US NIH Con-
sensus Development Program (http://consensus.nih.gov) and
adapted from the Methodological Handbook of the Italian
National Guideline System.8 The consensus conference method
is recommended for addressing important clinical questions in the
face of limited high-quality evidence. The main outcome, a
consensus statement, represents the collective opinions of an
expert panel, derived from systematic review and discussion of
available evidence.9 The Bologna Consensus Conference was
organized by the Istituto di Ricovero e Cura a Carattere
Scientifico (IRCCS) delle Scienze Neurologiche di Bologna,
Italy. Planning and execution was carried out in 4 phases: (1)
assignment, (2) scoping, (3) assessment, and (4) the consensus
conference itself. All activities were completed between
November 2013 and September 2014.
The project included 4 entities: (1) the Scientific Committee
(5 members) planned and organized the whole project, nomi-
nated Consensus Development Panel and Workgroup members,
performed the systematic review with evidence mapping, chose
the questions to be answered by the Workgroups, and established
methods and rules of the Consensus Conference; (2) the System-
atic Review and Technical Committee (4 members) assisted with
defining questions and the systematic review with evidence
mapping; (3) 3 Workgroups of experts (5 members each),
each focused on 1 relevant topic, synthesized and integrated
information from the systematic review before the consensus con-
ference, provided shared answers to the proposed questions, and
presented their findings during the Consensus Conference; (4)
the Consensus Development Panel (8 members) chaired the Con-
sensus Conference, established review and presentation proce-
dures, and provided final statements.
The systematic review was performed according to accepted
criteria for the conduct and reporting of systematic reviewse1
and reported according to PRISMA guidelines.e2 The descriptive
map of available research evidence (i.e., evidence mapping) was
performed by adapting the methodology reported by the Global
Evidence Mapping Initiative,e3 which involved detailed coding of
included studies and a series of in-depth syntheses in which the
available research was assessed in terms of, e.g., study design,
number of patients, and topic.
Studies eligible for inclusion in evidence mapping. Pub-
lished studies of any design, written in English, Italian, French,
or Spanish, were included. Studies were included if they reported
original data on patients with any type of motor complex behavior
during sleep of epileptic origin with possible frontal lobe involve-
ment. Reviews or concept papers and studies published only in
abstract form were excluded.
Search strategy. Published studies were identified from the
National Library of Medicine’s MEDLINE database, Elsevier’s
EMBASE database, or the Cochrane Central Register of Con-
trolled Trials by means of specific search strategies, using a com-
bination of exploded terms and free text combining 3 concepts:
motor phenomena in sleep, epilepsy, frontal lobe involvement
(see appendix e-1 on the Neurology® Web site at Neurology.org
for details). Finally, reference lists of identified articles were
reviewed to find additional references.
Study selection and quality appraisal. All abstracts or full pa-
pers without electronic abstracts were reviewed independently by
2 reviewers to identify potentially relevant studies. Disagreement
was resolved by a third reviewer. Subsequently, 2 reviewers inde-
pendently assessed studies for inclusion from the full text, with
disagreements resolved by a third reviewer. Each study was clas-
sified according to various descriptors (see appendix e-1), includ-
ing topic domain, sample size, design, presence of diagnostic
criteria of the syndrome, and quality of evidence according to
the Classification of Evidence Schemes of the Clinical Practice
Guideline Process Manual of the American Academy of
Neurology (2011).e4 Briefly, each study is graded according to
its risk of bias from Class I (highest quality) to Class IV (lowest
quality). Risk of bias is judged by assessing specific quality
elements (i.e., study design, patient spectrum, data collection,
masking) for each clinical topic (causation, diagnostic accuracy,
prognostic accuracy, therapeutic). As this classification does not
consider molecular genetic studies, these were assessed using the
checklist proposed for molecular studies from the Clinical
Genetics Society,e5 which also provides a 4-level classification
scheme with decreasing quality from 1 to 4 by assessing specific
quality elements (e.g., study design, evidence of altered function
of a gene product, evidence of genomic structure conserved across
species). This classification was performed by 3 reviewers, with
disagreement resolved by discussion.
SYSTEMATIC REVIEWWITH EVIDENCEMAPPING
The literature search was performed in December
2013 and April 2014, and retrieved 1,540 citations
after duplicate removal (figure). Each retrieved arti-
cle was screened to assess potential relevance, and
Neurology 86 May 10, 2016 1835
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
329 were reviewed from the full text for inclusion. A
total of 197 studies finally met the prespecified
inclusion criteria. See appendix e-1 for bibliometric
details.
According to simple descriptors (table), the major-
ity of studies were of low quality. Most included fewer
than 10 patients (57%), were case series or case
reports (78%), and did not report a definition of
the syndrome (85%). Analytic designs (cohort, case-
control) were used in only 19% of studies. The topics
most frequently considered were clinical semiology
(71%), neurophysiology (68%), etiology (64%),
therapy (51%), and genetics (36%). Only 9% of
the studies addressed epidemiology, diagnosis, or
prognosis.
NOMENCLATURE The 2 major outcomes of the
consensus conference were the need to change
nomenclature and the need to recognize the disorder
as a distinct epilepsy syndrome.
The new name proposed is sleep-related hypermo-
tor epilepsy (SHE). Although the name NFLE has
historical significance, 3 critical issues (discussed
and referenced below), justified this change. First,
the term nocturnal was considered misleading
because it implies a chronobiological pattern of sei-
zure occurrence, whereas evidence indicates that
occurrence in sleep is the most important characteris-
tic, whether at night or during daytime naps. Second,
the emphasis on localization to the frontal lobe was
considered misleading in view of evidence that the
characteristic seizures may also arise from other cere-
bral regions. Third, the original name did not specify
the typical clinical semiology involved, which consists
primarily of hypermotor seizures, and may also
include attacks with predominantly tonic or dystonic
features. In proposing this name, the consensus panel
recognized a logical inconsistency in that the term hy-
permotor describes a seizure type rather than an epi-
lepsy type; however, this is also true of several other
widely accepted syndrome names (e.g., progressive
myoclonus epilepsy, childhood absence epilepsy).
The consensus was that the simplicity and ease of
recall of SHE was more important than this con-
cern. In addition, although the consensus panel
acknowledged that the clinical semiology of the
syndrome is not fully captured by “hypermotor,”
they accepted this term because the full syndrome
description incorporates additional details about
clinical presentation.
At the present state of knowledge, SHE is best re-
garded as a single syndrome; neither constellations of
clinical features nor presence of comorbidities yet jus-
tifies the delineation of separate syndromes within
SHE. Although SHE has diverse etiologies, it is
defined by clinical manifestations (hypermotor seiz-
ures) possibly resulting from shared downstream
mechanisms occurring during sleep/wake oscilla-
tion changes, suggesting a unique pathogenic net-
work.10,11,e6 Moreover, consideration of SHE as a
single syndrome is most useful in clinical practice,
because the syndrome requires a distinct diagnostic
and therapeutic approach.
So far, only the autosomal dominant form of the
syndrome (previously ADNFLE) is included within
the guidelines proposed by the International League
Against Epilepsy Commission on Classification and
Terminology.12 Thus, the description of SHE within
this article expands the phenotype and clarifies iden-
tifying features of this syndrome on the basis of avail-
able evidence.
CLINICAL FEATURES Statements regarding clinical
features of SHE were formulated based on core liter-
ature consisting of studies of Class III level7,13–16 or
Class IV level.5,17–19
• SHE is characterized by the occurrence of brief
(,2 minutes) seizures with stereotyped motor
patterns within individuals and abrupt onset
and offset.5,7,13–19
Figure Preferred Reporting Items for Systematic Reviews and Meta-Analyses
flow diagrame2
Process and result of the systematic search for studies on nocturnal frontal lobe epilepsy.
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Table Descriptive features of published studies on sleep-related hypermotor epilepsy (SHE)a–related topics
Topic
All studies,
n (%)
Studies with ‡10
patients, n (%) Age,b n (%)
ADSHE/SHE,c
n (%)
Definition of SHE
reported, n (%)
Cohort
studies, n (%)
Case-control
studies, n (%)
Cross-sectional
studies, n (%)
Case series/family
series, n (%)
Case report/family
reports, n (%)
All studies 197 (100) 85 (43) 74 (38) children, 155
(79) adults
79 (40) ADSHE,
105 (53) SHE
30 (15) 6 (3) 31 (16) 6 (3) 96 (49) 58 (29)
Proof-of-concept 25 (13) 10 (40) 10 (40) children, 21
(84) adults
— 1 (4) — 2 (8) — 7 (28) 16 (64)
Boundary topics 25 (13) 9 (36) 12 (48) children, 20
(80) adults
— 5 (20) 2 (8) 1 (4) — 13 (52) 9 (36)
Etiology 127 (64) 52 (41) 52 (41) children, 95
(75) adults
61 (48) ADSHE, 67
(53) SHE
20 (16) 4 (3) 12 (9) 2 (2) 65 (51) 44 (34)
Genetic 71 (36) 39 (55) 24 (34) children, 57
(80) adults
60 (85) ADSHE, 17
(24) SHE
5 (7) — 11 (15) — 43 (61) 17 (24)
Epidemiology 2 (1) 2 (100) 1 (50) children, 2
(100) adults
2 (100) SHE 2 (100) — 2 (100) — — —
Clinical features 140 (71) 52 (37) 55 (39) children, 115
(82) adults
53 (38) ADSHE, 83
(59) SHE
20 (14) 2 (1) 12 (9) 1 (1) 75 (54) 50 (36)
Electroclinical
features
133 (68) 44 (33) 55 (41) children, 107
(80) adults
41 (31) ADSHE, 79
(59) SHE
20 (15) 1 (1) 12 (9) 3 (2) 71 (53) 46 (35)
Diagnosis 8 (4) 6 (75) 4 (50) children, 7 (88)
adults
2 (25) ADSHE, 7
(88) SHE
3 (38) 1 (13) 4 (50) 2 (25) 1 (13) —
Prognosis 8 (4) 7 (88) 3 (38) children, 8
(100) adults
2 (25) ADSHE, 4
(50) SHE
4 (50) 2 (25) 3 (38) 1 (1) 2 (25) —
Therapy 100 (51) 28 (28) 43 (43) children, 82
(82) adults
29 (29) ADSHE, 64
(64) SHE
16 (16) 1 (1) 5 (5) — 49 (49) 45 (45)
aSHE/autosomal dominant SHE 5 nocturnal frontal lobe epilepsy/autosomal dominant nocturnal frontal lobe epilepsy.
bNumber of studies including children or adults. Some studies included both, or did not specify any age.
cNumber of studies including ADSHE or SHE patients. Some studies included both, or did not report any diagnostic label.
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• The most common clinical expression consists
of “hypermotor” events.5,7,13–15,17–19
• Seizures of SHE occur predominantly during
sleep; however, seizures during wakefulness
may also occur.5,17–19
SHE is a rare form of focal epilepsy, with an
estimated minimum prevalence of 1.8/100,000 indi-
viduals, fulfilling the definition of rare disease.20 SHE
affects both sexes, and involves sleep-related seizures
with various motor manifestations.5,17 Seizure onset
may be at any age with a peak during childhood and
adolescence.5,17 Seizure frequency may be very high,
with occurrence either every night or almost every
night, usually many times per night.13,17 Clustering is
characteristic but not obligatory for diagnosis. Seizures
occur predominantly during sleep (and consequently
most commonly during the night), primarily in non-
REM (NREM) sleep and rarely during REM sleep.
Seizures during active wakefulness may also occasion-
ally occur during the patient’s lifetime. The first occur-
rence of these seizures may precede, coincide, or follow
the onset of sleep-related seizures.17
Seizures are abrupt in onset and offset, typically
brief (,2 minutes), and have a highly stereotyped
motor pattern within individuals.13–15,17 The primary
clinical expression consists of “hypermotor” events,21
characterized by vigorous hyperkinetic features (com-
plex body movements with kicking or cycling of limbs
and rocking body movements7), usually with vegeta-
tive signs, vocalization, and emotional facial expres-
sion.7,17 Asymmetric tonic/dystonic seizures with or
without head/eye deviation are also observed.5,17
Seizures may be preceded by abrupt arousal or a
distinct aura.5,18 Awareness of episodes is not uncom-
mon.18,22 Typically, patients with SHE present a
series of sleep-related motor events becoming increas-
ingly long and complex, even on the same night.
Clinical features range from brusque stereotyped
arousals (i.e., paroxysmal arousal17 or minor motor
events23), repeated throughout the night or arising
intermittently, with an almost periodic pattern, to
complex hypermotor seizures as described above
and, more seldom, protracted ambulatory behavior
known as epileptic nocturnal wandering.17,22,24,25
These events can last longer than 2 minutes. These
different seizure manifestations tend to coincide in
the same patient, with the shorter events developing
into more prolonged and complex attacks.17,22 Pa-
tients with SHE may complain of unsatisfactory sleep
and daytime tiredness. However, they do not have
significantly more daytime sleepiness than controls.26
Distinction from arousal parasomnias usually re-
lies on clinical history (frequency, clustering, and
timing with respect to sleep onset of the attacks),16
even though EEG–polysomnography (PSG) may be
required in some challenging cases. A personal or
familial history of arousal parasomnias is common
in patients with SHE, making shared pathophysio-
logic pathways plausible in these conditions.27,28
The majority of patients have normal intelligence.
However, intellectual disability and behavior disor-
ders have been reported in SHE,29 especially in the
familial form related to mutations in KCNT1,30 and
consequently are not exclusion criteria for SHE.
Response to medication has not been systematically
investigated. Carbamazepine is effective at low doses in
some patients with SHE, but this therapy seems to be
ineffective in at least one-third of patients,17 making
the response to antiepileptic drugs not discriminant for
SHE diagnosis. Surgery has been found to be effective
in some patients with severe, drug-resistant SHE
related to focal cortical dysplasia.13,31 Suspicion of a
genetic cause does not contraindicate presurgical eval-
uation, although data are still lacking on surgical out-
comes in patients with mutations in known genes.
ELECTROCLINICAL FEATURES Statements regard-
ing the electroclinical features of seizures in SHE are
based on core literature consisting of Class III
level13,16 or Class IV level5,17,19,22,32–36 studies.
• Interictal and ictal scalp EEG features may be
uninformative.5,13,17,19
• Prolonged video-EEG recording is the best
available diagnostic test to assess the occurrence
of seizures13,16 but, if negative, does not rule out
the diagnosis because seizures may not be re-
corded and interictal EEG abnormalities may
be absent.5,13,17,19
• Sleep-related hypermotor seizures may arise
from various frontal as well as from extrafrontal
areas.22,32–36
In many patients with SHE, the interictal and ictal
scalp EEG features are uninformative, especially
when seizures originate from the deep-seated cor-
tex.13,17 Prolonged video-EEG or, if available, PSG
recording, is the best tool to assess seizure occurrence
and is obligatory to characterize the abnormalities in
patients undergoing presurgical investigation.13 Sleep
staging by PSG may serve to differentiate SHE seiz-
ures from NREM parasomnias, the latter usually aris-
ing from stage 3 NREM sleep, even though this is not
a major element for the differential diagnosis.
PSG recordings show that increased sleep instabil-
ity is very common, particularly when multiple events
occur during sleep.10,25,37 Some studies suggest that
macrostructural sleep disturbances and arousal insta-
bility are part of the syndrome but this needs further
investigation.10,22,37
Intracranial recordings performed in drug-resistant
patients with SHE have clearly demonstrated that ictal
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discharge may arise not only from frontal lobe13,32
but also from various extrafrontal areas, including
insulo-opercular,33,34 temporal,35 and parietal36 cor-
tices, then propagating to frontal cortex and result-
ing in hypermotor seizures.e6 This might suggest the
ictal involvement of common cortico-subcortical
networkse7,e8 or a release phenomenon of stereo-
typed inborn fixed motor patterns.11
DIAGNOSTIC CERTAINTY Criteria for diagnostic
certainty of SHE were developed based on consensus
expert opinions and studies of Class III level.13,16,38
• Diagnosis of SHE is primarily based on clinical
history. The absence of clear interictal and ictal
EEG correlates, both during wakefulness and
sleep, does not exclude the diagnosis of SHE.13
• Certainty of diagnosis can be categorized into
3 levels: witnessed (possible) SHE, video-
documented (clinical) SHE, and video-EEG-
documented (confirmed) SHE.
Witnessed (possible) SHE. The main prerequisite to
suspect the diagnosis of SHE is the presence of seiz-
ures consisting of obvious and disruptive hypermotor
events, as described above. The semiologic aspects of
such events, as provided by an eyewitness, are gener-
ally concordant with those documented by video
analysis.16 Hence, data from a good clinical history
are sufficient to make the diagnosis of witnessed (pos-
sible) SHE.
Video-documented (clinical) SHE. Clinically diagno-
sed SHE requires audio-video documentation of
hypermotor events. In such a video recording, at
least 1 event but preferably 2 entire events should
be documented (confirmed to be typical by witness),
including the onset and with clear visualization of
the entire events, showing the evolution and offset
of the attacks. If the captured episodes are minor
motor events or paroxysmal arousals, and if few
episodes are captured, the clinical diagnosis may be
unreliable.16,38,39
Video-EEG-documented (confirmed) SHE. A confirmed
diagnosis of SHE requires video-EEG documentation
of the events during a daytime sleep recording after
sleep deprivation, or during a full night sleep
recording, with at least 19 EEG channels (10–20
International System), ECG, oculogram, and chin
EMG. SHE is confirmed when hypermotor seizures
are recorded during sleep, associated with a clear-cut
epileptic discharge or with interictal epileptiform
abnormalities.
ETIOLOGY/GENETICS Statements about etiology
were formulated based on core literature consisting
of clinical studies of Class III level5,18,31,40 and Class
IV level17,19 or genetic molecular studies of Class
1 level,41,42 Class 2 level,6,30,43 or Class 3 level.44,45
• In a majority of patients, the etiology is
unknown.17
• Identified etiologies are heterogeneous and
include structural anomalies such as focal corti-
cal dysplasia, acquired injuries, and genetic
causes.5,6,18,30,31,40–45
• No specific clinical features distinguish
etiologies.5,17,19
A majority of individuals with SHE do not have a
family history or other identified etiologies. In some
patients with drug-resistant SHE, the etiology may
involve a surgically treatable lesion, in particular type
II focal cortical dysplasia.31,40
Familial and sporadic SHE show similar clinical
features.5,17,19 Autosomal dominant SHE (ADSHE;
previously ADNFLE) is characterized by marked
intrafamilial variation in severity.18 A minority of
familial cases has a known genetic mutation. While
de novo mutations were first identified in rare cases
more than a decade ago,44 few sporadic cases have a
known genetic cause. Even in cases with a family
history, an autosomal dominant pattern of inheri-
tance is not frequent; the mode of inheritance is
unclear in most cases.
It was in ADSHE that the first epilepsy gene,
CHRNA4, was discovered.6,18 This was the first of 3
genes encoding subunits of the neuronal acetylcho-
line receptor (nAChR) to be implicated in ADSHE
(CHRNB2, CHRNA2).41,42 The phenotype produced
by mutations of the 3 nAChR subunit genes is gen-
erally indistinguishable.46 A more severe form of
ADSHE has been described in which some individ-
uals have intellectual disability, regression, and
behavioral and psychiatric disorders (depression, psy-
chosis, aggression, and personality disorder).29 Severe
ADSHE has been associated with mutations of the
sodium-activated potassium channel encoded by
KCNT1.30 Interestingly, the same gene is mutated
in a far more severe epileptic encephalopathy, epilepsy
with migrating focal seizures of infancy (MFSI).47
Functional studies show phenotype–genotype corre-
lation with a greater gain of function in MFSI than in
ADSHE.48
In some families with ADSHE, mutations have
been found in DEPDC5, a gene originally implicated
in familial focal epilepsy with variable foci
(FFEVF).49,50 SHE has long been recognized as a phe-
notype within FFEVF51 and in some families, espe-
cially smaller ones, the phenotype may be exclusively
SHE.43,45,50 DEPDC5 encodes a repressor of the
mammalian target of rapamycin (mTOR) pathway,
a key regulator of cell growth.52 This newly recog-
nized component of the mTOR pathway means that
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this pathway may be more critical to common focal
epilepsy than previously appreciated, suggesting that
mTOR inhibitors, which are effective in the arche-
typal mTORpathy, tuberous sclerosis, may have more
widespread application in focal epilepsies.53
RESEARCH NEEDS The main research gaps in SHE
regard epidemiology, pathophysiology, prognosis,
genetics, and targeted therapy.
Population-based studies are needed to estimate
the incidence and prevalence of SHE20 and could
also be used to provide critical information about
prognosis and remission rates, comorbidities, and
mortality compared to other focal epilepsies. Multi-
center studies of the familial co-occurrence of SHE
with arousal parasomnias are needed to elucidate
potential shared genetic susceptibility to these 2
disorders.27
In a retrospective cohort of patients with SHE,
incidence of sudden unexpected death in epilepsy
(SUDEP) was 0.36 per 1,000 person-years, not higher
than in prevalent epilepsy populations.54 This paucity
of reported SUDEP in SHE is notable, given the daily
occurrence of seizures during sleep and the previous
demonstration that occurrence of nocturnal seizures is
a risk factor for SUDEP after adjustment for general-
ized tonic-clonic seizures.55 The lower than expected
risk of SUDEP in SHE might reflect a low occurrence
of generalized tonic-clonic seizures in SHE.54
Improved structured instruments for clinical diag-
nosis of SHE are needed for epidemiologic and
genetic studies. Multicenter studies are needed to elu-
cidate the SHE spectrum and natural history, ranging
from clear-cut cases to atypical forms overlapping
with parasomnias. Home video recordings during
sleep may also have utility for improving diagnostic
accuracy, and additional multicenter studies are
needed to validate this approach. Although a key
role of genetic factors is well-known in autosomal
dominant SHE, a minority of familial cases and rare
sporadic cases have a known genetic cause. Next-
generation sequencing will enable the identification
of additional susceptibility genes in SHE, and the fre-
quency of mutations in specific genes can subse-
quently be established through targeted mutation
testing in large cohorts. Family studies may also pro-
vide insights into genetically based phenotypic varia-
tion and alternative inheritance patterns of SHE such
as recessive or polygenic models.
The increasingly recognized role of de novo and
somatic mutations in human disease is highly relevant
to SHE.56 Sporadic cases may have de novo mutations
of genes with high penetrance or genes with smaller
effects conferring risk in polygenic or multifactorial
settings. The identification of postzygotic, somatic
mutations in brain as causes of malformations such
as hemimegalencephaly57,58 suggests that other brain
diseases may be due to somatic mutations. Such mu-
tations may be identifiable only in brain tissue from
patients undergoing epilepsy surgery, or may be pre-
sent in other tissues such as blood and saliva due to
mosaicism.
Some individuals in families with DEPDC5 muta-
tions have malformations of cortical development, espe-
cially focal cortical dysplasia.59 Given the role of
DEPDC5 as an inhibitor of the mTOR pathway, a
key question is whether a second-hit mutation is pre-
sent in the brain tissue of an individual with aDEPDC5
mutation. This can be addressed with whole-exome
sequencing of tissue removed for refractory epilepsy
and may improve understanding of the molecular
pathology of malformations of cortical development.
Finally, genetic findings may serve as the basis for
development of targeted therapies for SHE. An early
example of the potential of this approach is the success-
ful use of quinidine for treatment of a patient with an
epileptic encephalopathy caused by a de novo KCNT1
mutation,60 following the finding that it reverses the
gain of function of the mutant potassium channel
in vitro.30,48 These and similar developments provide
promise for understanding and precision medicine
strategies for treatment of this intriguing syndrome.
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